Suppr超能文献

将二甲双胍重新用于牙周病管理,作为一种口腔-全身预防医学形式。

Repurposing Metformin for periodontal disease management as a form of oral-systemic preventive medicine.

机构信息

Centre for Craniofacial and Regenerative Biology, FoDOCS, King's College London, London, UK.

Periodontology Unit, Centre for Host-Microbiome Interactions, FoDOCS, King's College London, London, UK.

出版信息

J Transl Med. 2023 Oct 10;21(1):655. doi: 10.1186/s12967-023-04456-1.

Abstract

BACKGROUND

Despite the improvements in treatment over the last decades, periodontal disease (PD) affects millions of people around the world and the only treatment available is based on controlling microbial load. Diabetes is known to increase the risk of PD establishment and progression, and recently, glucose metabolism modulation by pharmaceutical or dietarian means has been emphasised as a significant modulator of non-communicable disease development.

METHODS

The impact of pharmaceutically controlling glucose metabolism in non-diabetic animals and humans (REBEC, UTN code: U1111-1276-1942) was investigated by repurposing Metformin, as a mean to manage periodontal disease and its associated systemic risk factors.

RESULTS

We found that glucose metabolism control via use of Metformin aimed at PD management resulted in significant prevention of bone loss during induced periodontal disease and age-related bone loss in vivo. Metformin also influenced the bacterial species present in the oral environment and impacted the metabolic epithelial and stromal responses to bacterial dysbiosis at a single cell level. Systemically, Metformin controlled blood glucose levels and age-related weight gain when used long-term. Translationally, our pilot randomized control trial indicated that systemic Metformin was safe to use in non-diabetic patients and affected the periodontal tissues. During the medication window, patients showed stable levels of systemic blood glucose, lower circulating hsCRP and lower insulin levels after periodontal treatment when compared to placebo. Finally, patients treated with Metformin had improved periodontal parameters when compared to placebo treated patients.

CONCLUSION

This is the first study to demonstrate that systemic interventions using Metformin in non-diabetic individuals aimed at PD prevention have oral-systemic effects constituting a possible novel form of preventive medicine for oral-systemic disease management.

摘要

背景

尽管过去几十年来治疗方法有所改进,但牙周病(PD)仍影响着全球数百万人,而现有的唯一治疗方法是基于控制微生物负荷。糖尿病已被证实会增加 PD 发生和进展的风险,最近,通过药物或饮食手段调节葡萄糖代谢已被强调为调节非传染性疾病发展的重要手段。

方法

通过重新利用二甲双胍来控制非糖尿病动物和人类的葡萄糖代谢(REBEC,UTN 编号:U1111-1276-1942),研究了控制葡萄糖代谢对牙周病及其相关系统性危险因素的影响。

结果

我们发现,通过使用二甲双胍来控制葡萄糖代谢以管理 PD,可显著预防诱导性牙周病和体内年龄相关性骨丢失。二甲双胍还影响口腔环境中的细菌种类,并在单细胞水平上影响代谢上皮和基质对细菌失调的反应。在系统层面,长期使用二甲双胍可控制血糖水平和年龄相关性体重增加。从转化医学的角度来看,我们的初步随机对照试验表明,系统性使用二甲双胍在非糖尿病患者中是安全的,并影响牙周组织。在用药窗口期,与安慰剂相比,牙周治疗后接受二甲双胍治疗的患者全身血糖水平稳定,循环 hsCRP 和胰岛素水平降低。最后,与安慰剂治疗的患者相比,接受二甲双胍治疗的患者牙周参数得到改善。

结论

这是第一项证明针对 PD 预防的非糖尿病个体使用二甲双胍进行系统性干预具有口腔-系统效应的研究,构成了一种针对口腔-系统疾病管理的新型预防医学形式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/286b/10563330/fb0e703e23d4/12967_2023_4456_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验